|
Researchers
report continued improvement in motor function and quality
of life for Parkinson's patients treated with Spheramine®
in a clinical study being performed at Emory University in
Atlanta.
Presenting
interim study results to the International Congress on Parkinson's
Disease in Helsinki, Dr. Ray L. Watts, Professor and Vice
Chairman of the Department of Neurology at Emory University
School of Medicine, said all 6 patients to date have experienced
substantial clinical improvement.
One patient
has completed 15 months on study, with two patients at approximately
10 months, and three patients at 7 months on study respectively.
All patients in this pilot study have demonstrated improvement,
with no safety concerns or significant adverse events, Watts
said. At 6 months post treatment, an average 33 percent improvement
was reported, with a 40 percent improvement at nine months.
"All
patients in this study have to date demonstrated significant
improvement in motor function, as well as improved quality
of life," said Watts. "This improvement continues
for all patients on study, and in the case of the longest
patient on study, now extends beyond one year. Although preliminary,
these results suggest that Spheramine may be one of the more
promising agents in development for treatment of Parkinson's
disease."
"We
are very pleased with the continued excellent progress of
this study," said Dr. Louis R. Bucalo, Chairman and CEO
of Titan Pharmaceuticals, Inc. "The level and consistency
of clinical improvement demonstrated in these preliminary
results, and good safety profile to date suggest that Spheramine
may be an important new potential therapy for Parkinson's
disease."
Source:
Medical Week staff,
week of August 5, 2001
|
HOME PAGE
